Roche has received the CE Mark for its new assay designed to detect bacterial vaginosis and candida vaginitis. This regulatory approval allows the product to be marketed in European countries and is a significant advancement in women’s health diagnostics. The assay aims to provide accurate and rapid results for clinicians, helping to improve patient outcomes by facilitating timely treatment.
The test is expected to enhance the existing diagnostic options available for these common conditions, which can cause discomfort and affect quality of life. With this CE Mark, Roche is positioned to expand its portfolio in the field of women’s health, addressing a critical need for effective diagnostic tools.
Source: news.google.com